Latest News
All Times Eastern
- My wife wants us to spend $5,000 to attend her cousin’s destination wedding. I don’t want to go. Am I being selfish?
- ‘I feel used’: My partner stays with me 5 nights a week, even though he owns his own home. Should he pay for utilities and food?
- DeSantis promises to make America Florida. But Florida isn’t Florida anymore, critics say.
- Special counsel Durham to testify before House committee on June 20 about his investigate-the-investigators report
- From solemn reflection to ‘three-day hootenanny’: the evolution, and degradation, of the Memorial Day holiday
- How much does a mammogram cost? That depends on whether it’s ‘diagnostic’ or ‘screening.’
- How Joe Biden and Kevin McCarthy got to yes on their debt-ceiling compromise
- Global stock markets breathe a sigh of relief over Biden-McCarthy pact to avert U.S. debt default
- ‘He’s content living paycheck to paycheck’: My husband won’t work or get a driver’s license. Now things have gotten even worse.
- Don’t get stung by buy-now- pay-later services: ‘It is kind of a recipe for disaster if not managed carefully’
to be replaced
Amgen Inc.
AMGNUS
$
0.27
0.12%
After Hours
$
217.20
After Hours Volume:
269.16K
| Close | Chg | Chg % |
|---|---|---|
| $216.93 | -0.53 | -0.24% |
Volume: 3.08M
65 Day Avg: 2.26M
214.48
Day Range
218.48
214.48
52 Week Range
296.67
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
AMGN Overview
Key Data
- Open $215.96
- Day Range 214.48 - 218.48
- 52 Week Range 214.48 - 296.67
- Market Cap $115.91B
- Shares Outstanding 534.33M
- Public Float 533.11M
- Beta 0.65
- Rev. per Employee $1.029M
- P/E Ratio 14.74
- EPS $14.71
- Yield 3.93%
- Dividend $2.13
- Ex-Dividend Date May 17, 2023
- Short Interest 7.59M 05/15/23
- % of Float Shorted 1.42%
- Average Volume 2.26M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 26
Full Ratings
Recent News
Biotech and Pharma FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics
Biotech and Pharma Weight-Loss Drugs Will Be Blockbusters. Here’s the Stock to Buy.
3 Dogs of the Dow for High-Yield Investors
on InvestorPlace.com
Check Out What Whales Are Doing With AMGN
on Benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
on Benzinga.com
4 Best Biotech Stocks According to POWR Ratings
on StockNews.com
10 Health Care Stocks Whale Activity In Today's Session
on Benzinga.com
Amgen's Debt Overview
on Benzinga.com
3 Safe Dividend Stocks to Beat Inflation
on Motley Fool
Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron
on TipRanks.com
Top 5 1st Quarter Trades of INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Top 5 1st Quarter Trades of INTERNATIONAL BIOTECHNOLOGY TRUST PLC
on GuruFocus.com
Amgen’s Horizon Deal Won’t Close before September
on TipRanks.com
Amgen Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson | $401.11B | |
| Pfizer Inc. | $212.26B | |
| Novo Nordisk A/S Series B | kr.2.53T | |
| AbbVie Inc. | $242.7B | |
| AstraZeneca PLC ADR | $225.23B | |
| AstraZeneca PLC | £182.64B | |
| Moderna Inc. | $48.12B | |
| Gilead Sciences Inc. | $96.16B | |
| Regeneron Pharmaceuticals Inc. | $79.53B | |
| Lonza Group AG | CHF42.49B |